A New Line Of Communication Between Nervous System Cells Discovered By Weizmann Scientists
Main Category: Neurology / NeuroscienceAlso Included In: Multiple Sclerosis; Biology / Biochemistry
Article Date: 30 Jun 2007 - 13:00 PDT
| Patient / Public: | ![]() |
4.36 (11 votes) |
| Healthcare Prof: | ![]() |
5 (2 votes) |
| Article Opinions: | 1 posts |
In a host of neurological diseases, including multiple sclerosis (MS) and several neuropathies, the protective covering surrounding the nerves - an insulating material called myelin - is damaged. Scientists at the Weizmann Institute of Science have now discovered an important new line of communication between nervous system cells that is crucial to the development of myelinated nerves - a discovery that may aid in restoring the normal function of the affected nerve fibers.
Nerve cells (neurons) have long, thin extensions called axons that can reach up to a meter and or more in length. Often, these extensions are covered by myelin, which is formed by a group of specialized cells called glia. Glial cells revolve around the axon, laying down the myelin sheath in segments, leaving small nodes of exposed nerve in between. More than just protection for the delicate axons, the myelin covering allows nerve signals to jump instantaneously between nodes, making the transfer of these signals quick and efficient. When myelin is missing or damaged, the nerve signals can't skip properly down the axons, leading to abnormal function of the affected nerve and often to its degeneration.
In research published recently in Nature Neuroscience, Weizmann Institute scientists Prof. Elior Peles, graduate student Ivo Spiegel, and their colleagues in the Molecular Cell Biology Department and in the United States, have now provided a vital insight into the mechanism by which glial cells recognize and myelinate axons.
How do the glial cells and the axon coordinate this process" The Weizmann Institute team found a pair of proteins that pass messages from axons to glial cells. These proteins, called Necl1 and Necl4, belong to a larger family of cell adhesion molecules, so called because they sit on the outer membranes of cells and help them to stick together. Peles and his team discovered that even when removed from their cells, Necl1, normally found on the axon surface, and Necl4, which is found on the glial cell membrane, adhere tightly together. When these molecules are in their natural places, they not only create physical contact between axon and glial cell, but also serve to transfer signals to the cell interior, initiating changes needed to undertake myelination.
The scientists found that production of Necl4 in the glial cells rises when they come into close contact with an unmyelinated axon, and as the process of myelination begins. They observed that if Necl4 is absent in the glial cells, or if they blocked the attachment of Necl4 to Necl1, the axons that were contacted by glial cells did not myelinate. In the same time period, myelin wrapping was already well underway around most of the axons in the control group.
"What we've discovered is a completely new means of communication between these nervous system cells," says Peles. "The drugs now used to treat MS and other degenerative diseases in which myelin is affected can only slow the disease, but not stop or cure it. Today, we can't reverse the nerve damage caused by these disorders. But if we can understand the mechanisms that control the process of wrapping the axons by their protective sheath, we might be able to recreate that process in patients."
###
Prof. Elior Peles's research is supported by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; the Nella and Leon Benoziyo Center for Neurological Diseases; the Kekst Family Center for Medical Genetics; The David and Fela Shapell Family Center for Genetic Disorders; the Wolgin Prize for Scientific Excellence; the National Institutes of Health (NIH); the National Multiple Sclerosis Society; the US-Israel Binational Science Foundation; and the Israel Science Foundation.
The Weizmann Institute of Science in Rehovot, Israel, is one of the world's top-ranking multidisciplinary research institutions. Noted for its wide-ranging exploration of the natural and exact sciences, the Institute is home to 2,500 scientists, students, technicians, and supporting staff. Institute research efforts include the search for new ways of fighting disease and hunger, examining leading questions in mathematics and computer science, probing the physics of matter and the universe, creating novel materials, and developing new strategies for protecting the environment.
Contact: Jennifer Manning
American Committee for the Weizmann Institute of Science
Visit our neurology / neuroscience section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/75315.php>
APA
http://www.medicalnewstoday.com/releases/75315.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
We're Getting There
posted by Janis on 2 Jul 2007 at 9:35 pmI am always excited whenever I read an article or hear a report of progress toward understanding how demyelinization or remyelinization takes place in the brain and spinal cord. Especially exciting is the research into how the processes can be affected. As the article mentioned, the treatments so far only slow the disease process down. That's a huge only.
When I was in school in the early 1960s MS was the "Crippler" of young to middle aged adults with no known cause, no cure and no known treatment . The average life expectancy after diagnosis was 10 to 15 years. When I was diagnosed in the mid 70s not much had changed except the life expectancy was a bit longer. It's been only a dozen years since the first effective treatment, Betaseron, was released, the first new drug in over 20 years.
Since then there has been a comparative explosion of treatments and knowledge. I am still able to work today because in 1996 I started Avonex when it was first approved. Yes, every article like this serves to encourage those of us with a demyelinating desease as well as those of us who work in a health profession and treat those who do. I'm lucky enough to be both and therefore have double the excitement.
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




